TP53 and cancer: authors conclude that p53 is a valid biomarker that guides the radio-sensitization strategy towards Warburg effect inhibitors for mutant p53-expressing cancers and towards a combination of glycolysis and respiratory inhibitors for wild-type p53 cancers (40, 41).